Menu
Back to Archived Journals » Oncolytic Virotherapy » Volume 4 » default
Oncolytic Virotherapy ceased publishing in January 2023. All articles that have been published in Oncolytic Virotherapy will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.
ISSN: 2253-1572
- View all (70)
- Volume 10, 2021 (1)
- Volume 9, 2020 (2)
- Volume 8, 2019 (6)
- Volume 7, 2018 (11)
- Volume 6, 2017 (6)
- Volume 5, 2016 (10)
- Volume 4, 2015 (20)
- Volume 3, 2014 (8)
- Volume 2, 2013 (5)
- Volume 1, 2012 (1)
Archive: Volume 4, 2015
Oncolytic virotherapy using herpes simplex virus: how far have we come?
Sokolowski NAS, Rizos H, Diefenbach RJ
Oncolytic Virotherapy 2015, 4:207-219
Published Date: 25 November 2015
Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art
Nande R, Howard CM, Claudio PP
Oncolytic Virotherapy 2015, 4:193-205
Published Date: 25 November 2015
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
Nakashima H, Nguyen T, Chiocca EA
Oncolytic Virotherapy 2015, 4:183-191
Published Date: 20 November 2015
Targeting tumor vasculature through oncolytic virotherapy: recent advances
Toro Bejarano M, Merchan JR
Oncolytic Virotherapy 2015, 4:169-181
Published Date: 11 November 2015
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
Simovic B, Walsh SR, Wan YH
Oncolytic Virotherapy 2015, 4:157-167
Published Date: 15 October 2015
Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology
Ramírez M, García-Castro J, Melen GJ, González-Murillo A, Franco-Luzón L
Oncolytic Virotherapy 2015, 4:149-155
Published Date: 14 October 2015
Oncolytic Sendai virus-based virotherapy for cancer: recent advances
Saga K, Kaneda Y
Oncolytic Virotherapy 2015, 4:141-147
Published Date: 1 October 2015
Oncolytic virotherapy for human malignant mesothelioma: recent advances
Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF
Oncolytic Virotherapy 2015, 4:133-140
Published Date: 10 September 2015
Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor
Sakr HI, Coleman DT, Cardelli JA, Mathis JM
Oncolytic Virotherapy 2015, 4:119-132
Published Date: 4 September 2015
Advances in the design and development of oncolytic measles viruses
Hutzen B, Raffel C, Studebaker AW
Oncolytic Virotherapy 2015, 4:109-118
Published Date: 27 August 2015
On the potential of oncolytic virotherapy for the treatment of canine cancers
MacNeill AL
Oncolytic Virotherapy 2015, 4:95-107
Published Date: 26 August 2015
Oncolytic virotherapy for head and neck cancer: current research and future developments
Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM
Oncolytic Virotherapy 2015, 4:83-93
Published Date: 20 July 2015
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
Sampath P, Thorne SH
Oncolytic Virotherapy 2015, 4:75-82
Published Date: 18 June 2015
Promising oncolytic agents for metastatic breast cancer treatment
Cody JJ, Hurst DR
Oncolytic Virotherapy 2015, 4:63-73
Published Date: 3 June 2015
Therapeutic potential of oncolytic Newcastle disease virus a critical review
Tayeb S, Zakay-Rones Z, Panet A
Oncolytic Virotherapy 2015, 4:49-62
Published Date: 27 March 2015
Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy
Binz E, Lauer UM
Oncolytic Virotherapy 2015, 4:39-48
Published Date: 23 February 2015
Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy
Whisenhunt Jr TR, Rajneesh KF, Hackney JR, Markert JM
Oncolytic Virotherapy 2015, 4:33-38
Published Date: 30 January 2015
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J
Oncolytic Virotherapy 2015, 4:25-31
Published Date: 28 January 2015
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications
Tsang JJ, Atkins HL
Oncolytic Virotherapy 2015, 4:13-23
Published Date: 23 January 2015
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor–resistant multiple myeloma
Dunlap KM, Bartee MY, Bartee E
Oncolytic Virotherapy 2015, 4:1-11
Published Date: 13 January 2015